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large observational studies or randomized controlled trials were available involving a study population similar to that planned for the present study. However, a study using 60 patients in each treatment arm was calculated to have approximately 80% power to detect a standardized difference between treatment arms of approximately 0.50 units. This effect size is smaller than the standardized effect sizes reported by Jones et al. (Jones G, et al. Rheumatology. 2003; 42:6-13 .) for infliximab and leflunomide radiographic studies, and comparable with most of the effect size estimates reported in that paper for a range of DMARDs, given the expected greater sensitivity of the RAMRIS score.
Assignment to treatment group/sequence
Eligible patients were randomly assigned to treatment groups through an interactive voice response system (IVRS) prior to receiving any study medication. The specifications of the randomization algorithm were determined by the Roche randomization group in Basel, Switzerland and provided to Perceptive Informatics (Nottingham, UK) who provided the IVRS service. Central randomization was performed by the IVRS and stratified by duration of MTX treatment prior to entering the study (< 6 months or ≥ 6 months) and by presence or absence of bone erosions using the randomization list provided by the Sponsor.
Patient eligibility information was provided to the IVRS by the investigator at the time of randomization. During randomization, the patient was assigned a unique medication/ randomization number, which the investigator noted in the appropriate place on the eCRF.
Once randomized, the patient received treatment according to the schedule described in the main text. Rituximab infusions were to be given on an outpatient basis; however, it was acceptable to hospitalize a patient for 24 hours if required.
Blinding
This was a double-blind study. Consequently, details of the randomization list were available only to the 2 Randomization List Managers (Jean-Claude Farina and Norbert Neumann) and were not available at the study center, to the Sponsor's monitors, project statisticians or to the Sponsor's project team at any time prior to the Week 24 analysis.
It was only permissible to unblind a patient's treatment assignment when knowledge of the treatment was essential for the further management of the patient, such as in the event of an SAE or if an independent pharmacological analysis of biological samples was required. In such cases, it was necessary to ensure that adequate procedures were in place to ensure integrity of the data.
The investigator had to make every attempt to contact the Sponsor before unblinding the treatment assignment for any patient, but if this was not possible, he/she had to contact the Sponsor within 1 working day after the event and, if appropriate, complete an AE form. In the event of accidental unblinding, all the above procedures had to be followed, but no AE form had to be completed.
If emergency unblinding was required, the investigator or designee contacted the IVRS prior to unblinding a patient. The IVRS then provided the site with the patient's unblinding code.
Additionally, to maintain the blind after screening, sites did not receive data related to RF, anti-CCP, CD19, rituximab serum levels or HACA results. CD19+ cell counts were made available to the investigator at the end of the first year of SFU in order that a decision could be made as to whether or not to continue to follow the patient.
The first database lock for the study occurred for the purposes of the Week 24 analysis, which included primary, secondary and exploratory efficacy analyses and safety summaries, once all data up to that point had been collected and cleaned.
Treatment assignments were unblinded to the Sponsor at this point. However, all patients and investigators/assessors remained blinded to treatment assignments until the end of the study. 
SUPPLEMENTARY TABLES

(1.7)
Papillary serous endometrial carcinoma   1 (1.7)
Pregnancy, puerperium, and perinatal conditions  
Omphalorrhexis   1 (1.7)
Renal and urinary disorders 
